ABVC BioPharma Reports 179% Asset Growth in 2025, Shifts Toward Hybrid Business Model

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, revealing substantial balance sheet growth and strategic long-term asset positioning. Total assets increased to $21,062,203, compared to $7,539,907 in 2024, representing a 179% year-over-year increase. Net property and equipment rose to $12,835,409, up from $511,088 in the prior year, primarily driven by strategic acquisition of land and development-oriented land assets in Asia. Management believes the 2025 fiscal year represents a structural strengthening of the company's balance sheet and asset foundation.

The company has strategically licensed its core drug programs to subsidiaries and related parties, including its CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, subsidiaries and related parties handle advancing clinical development while ABVC reduces direct clinical cash burn exposure and retains licensing economics and equity participation. This model enables ABVC to separate development risk from long-term value participation while preserving upside and mitigating capital intensity.

In parallel with its licensing framework, ABVC is strengthening its long-term infrastructure positioning in Asia through strategic land asset acquisitions. The Longtan property in Taoyuan, valued at $4.6 million as of December 31, 2025, comprises 5,995.41 square meters and is being held as a strategic reserve asset with flexible future use potential. The Puli property in Nantou, comprising 69,230.90 square meters, was independently appraised as of January 30, 2026, at approximately USD $8.0 million. The Puli development plan is designed as a staged, long-term initiative focused on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, creating an agricultural-biotech integration platform, and developing value-added processing and storage infrastructure.

The potential for substantial increase in fixed and real assets reflects ABVC's strategic evolution toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. This transition from a purely IP-driven biotech structure represents a significant shift in the company's business approach. The company's filings with the Securities and Exchange Commission provide more detailed information about risk factors that may affect forward-looking statements, available free of charge on the SEC's website at http://www.sec.gov.